Anticoagulant Therapy Management Quiz

Common indication for anticoagulant therapy due to increased risk of thromboembolic events.

Monitors warfarin's effect on coagulation by measuring clotting time.

Hypertension, while a risk factor for cardiovascular events, does not typically require anticoagulant therapy.

Hypertension is not a common adverse effect of anticoagulant therapy.

Hematoma formation can occur as a complication of anticoagulant therapy due to increased bleeding tendency.

DOACs directly inhibit factor Xa, interrupting the coagulation cascade.

Dabigatran directly inhibits thrombin, an essential enzyme in the clotting cascade.

Dabigatran levels may need monitoring due to its renal elimination and variable pharmacokinetics.

Heparin enhances antithrombin's ability to inhibit thrombin and factor Xa.

Fondaparinux indirectly inhibits factor Xa by enhancing antithrombin activity.

Anticoagulant therapy is typically continued indefinitely for unprovoked DVT to prevent recurrence.

Vitamin K reverses the anticoagulant effect of warfarin by replenishing clotting factors.

Blood type is not relevant to anticoagulant therapy selection.

Dabigatran requires renal dose adjustment due to its primarily renal elimination.

DOACs have more predictable pharmacokinetics and do not require routine monitoring compared to warfarin.

Warfarin is the recommended anticoagulant for mechanical heart valves due to its efficacy and reversibility.

LMWH has more predictable pharmacokinetics and dosing, making it easier to manage compared to UFH.